Managing follicular lymphoma

Share this content:

the ONA take:

Changes in how follicular lymphoma (FL) is managed have led to substantial improvement in prognosis and over all survival. Some patients with limited disease stages I and II may achieve durable response from radiotherapy; however, whether these patients are cured is unclear. New approaches such as combination therapy (eg, irradiation with rituximab) or single-agent rituximab should be explored. The current standard for stage III and IV disease with low tumor burden is a watch and wait strategy, but better indices are needed for selecting patients for whom early intervention is preferred. Immunochemotherapy followed by 2 years of rituximab maintenance is widely accepted as standard therapy for advanced stages with high tumor burden; however, retreatment may be an alternative option for recurrent disease. In addition, new therapeutic options have recently arisen from new antibodies, as well as new targeted therapies and immunomodulatory drugs that may lead to chemotherapy-free therapies in the near future.

Managing follicular lymphoma
Managing follicular lymphoma
Major changes have taken place within the last few years in the management of follicular lymphoma (FL) leading to substantial improvement in prognosis and overall survival. For some patients with limited disease stages I and II, radiotherapy may be associated with durable responses.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs